Alphacetylmethadol

Alphacetylmethadol

Alphacetylmethadol (also known as ACEM or LAAM) is a synthetic opioid used in the treatment of opioid addiction. It is a long-acting derivative of methadone and is chemically similar to levo-alpha-acetylmethadol (LAAM).

History

Alphacetylmethadol was first synthesized in the 1940s as part of a research program aimed at developing opioid analgesics with improved pharmacological properties. It was later developed as a treatment for opioid addiction in the 1970s.

Pharmacology

Alphacetylmethadol is a mu-opioid receptor agonist. It works by mimicking the effects of opioids in the brain, thereby reducing cravings and withdrawal symptoms in opioid-dependent individuals. Alphacetylmethadol is metabolized in the liver and has a long half-life, which allows for less frequent dosing compared to other opioid replacement therapies.

Clinical Use

Alphacetylmethadol is used in the treatment of opioid addiction. It is typically administered in a clinic setting under the supervision of a healthcare provider. The dosage is individualized based on the patient's opioid tolerance and response to treatment.

Side Effects

Common side effects of alphacetylmethadol include constipation, drowsiness, and nausea. Serious side effects may include respiratory depression, QT prolongation, and dependence.

Legal Status

In the United States, alphacetylmethadol is classified as a Schedule II controlled substance, indicating a high potential for abuse and dependence.

See Also

• Methadone
• Opioid addiction
• Opioid replacement therapy

‎